Porton(SZ:300363)2022-12-07 08:46Group 1: Financial Performance - The company's revenue growth in Q4 last year was significant, but this year's Q4 performance is sensitive information and cannot be disclosed [1] - The company's multi-client product business grew nearly twofold in the first half of this year, attributed to internal business growth rather than the acquisition of Dongbang Pharmaceutical [1] Group 2: Production Capacity - The company has approximately 600 cubic meters of commercial production capacity and about 400 cubic meters of pilot production capacity at its Changshou production base [2] - The company’s subsidiary, Zhejiang Boten, has around 180 cubic meters of pilot production capacity, while the recently acquired Jiangxi Dongbang Pharmaceutical has about 300 cubic meters of multifunctional product capacity [2] Group 3: Research and Development - The Chengdu and Chongqing R&D centers support the Chongqing production base, focusing on new product development, especially GMP products [2] - The Shanghai R&D center, which supports the Zhejiang Shangyu production base, is dedicated to early-stage non-GMP product development and FTE project development [2] Group 4: Financial Metrics - The fixed asset depreciation for the first half of this year was approximately 23 million [3] - The gross margin for innovative pharmaceutical raw materials is higher than that of intermediates, with foreign reports indicating that biological CMO gross margins are also higher [3]